Markus Joerger

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 15

Top Topics

Advanced Non Small Cell Lung Cancer

Histone Deacetylase

Prognostic Factors

Top Venues

Cancer management and research

Cancer chemotherapy and pharmacology

Journal of personalized medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Markus Joerger, Kira-Lee Koster, Tomas Janik, Floris A de Jong
Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents. Cancer management and research 16 (2024)
Markus Joerger, Kira-Lee Koster, Tomas Janik, Floris A de Jong
Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents. Cancer management and research 16 (2024)
Yomna M Nassar, Francis Williams Ojara, Alejandro Pérez-Pitarch, Kimberly Geiger, Wilhelm Huisinga, Niklas Hartung, Robin Michelet, Stefan Holdenrieder, Markus Joerger, Charlotte Kloft
C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework. Cancers 15 (22) (2023)
Aurelius G Omlin, Richard Cathomas, Gunhild von Amsberg, Christoph Reuter, Susan Feyerabend, Wolfgang Loidl, Martin Boegemann, Anja Lorch, Axel Heidenreich, Igor Tsaur, Julian Larcher-Senn, Stefan A J Buck, Ron H J Mathijssen, Ulrich Jaehde, Silke Gillessen Sommer, Markus Joerger
Randomized phase 2 Cabazitaxel dose individualization and Neutropenia prevention Trial (CAINTA) in patients with metastatic castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Kira-Lee Koster, Jens Huober, Markus Joerger
New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development. Exploration of targeted anti-tumor therapy 3 (1) (2022)
Markus Joerger, Yannis Metaxas, Khalil Zaman, Olivier Michielin, Nicolas Mach, Adrienne Bettini, Andreas Michael Schmitt, Nathan Cantoni, Clemens B Caspar, Sonja Stettler, Roma Malval, Miklos Pless, Christian Britschgi, Christoph Renner, Dieter Koeberle, Jessica D Schulz, Christoph Kopp, Stefanie Hayoz, Anastasios Stathis, Roger von Moos, null null
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). Cancers 14 (9) (2022)
Fiamma Berner, David Bomze, Christa Lichtensteiger, Vincent Walter, Rebekka Niederer, Omar Hasan Ali, Nina Wyss, Jens Bauer, Lena Katharina Freudenmann, Ana Marcu, Eva-Maria Wolfschmitt, Sebastian Haen, Thorben Gross, Marie-Therese Abdou, Stefan Diem, Stella Knöpfli, Tobias Sinnberg, Kathrin Hofmeister, Hung-Wei Cheng, Marieta Toma, Niklas Klümper, Mette-Triin Purde, Oltin Tiberiu Pop, Ann-Kristin Jochum, Steve Pascolo, Markus Joerger, Martin Früh, Wolfram Jochum, Hans-Georg Rammensee, Heinz Laubli, Michael Hudecek, Jacques J C Neefjes, Juliane Sarah Walz, Lukas Flatz
Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Science immunology 7 (75) (2022)
Anna M Mc Laughlin, Lena Klopp-Schulze, Robin Michelet, Madelé van Dyk, Thomas E Mürdter, Matthias Schwab, Markus Joerger, Wilhelm Huisinga, Gerd Mikus, Charlotte Kloft
Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies. Pharmaceuticals (Basel, Switzerland) 14 (2) (2021)
Anna M Mc Laughlin, Eduard Schmulenson, Olga Teplytska, Sebastian Zimmermann, Patrick Opitz, Stefanie L Groenland, Alwin D R Huitema, Neeltje Steeghs, Lothar Müller, Stefan Fuxius, Gerald Illerhaus, Markus Joerger, Frank Mayer, Uwe Fuhr, Stefan Holdenrieder, Georg Hempel, Oliver Scherf-Clavel, Ulrich Jaehde, Charlotte Kloft, null For The On-Target Study Consortium
Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. Cancers 13 (24) (2021)
Anna M Mc Laughlin, Robin Michelet, Lena Klopp-Schulze, Madelé van Dyk, Thomas E Mürdter, Matthias Schwab, Markus Joerger, Wilhelm Huisinga, Gerd Mikus, Charlotte Kloft
Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups. Cancers 13 (10) (2021)
Dominic Schaerer, Tanja K Froehlich, Seid Hamzic, Steven M Offer, Robert B Diasio, Markus Joerger, Ursula Amstutz, Carlo R Largiadèr
A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies. Journal of personalized medicine 10 (4) (2020)
Andreas Schneeweiss, Dagmar Hess, Markus Joerger, Andrea Varga, Stacy Moulder, Apostolia M Tsimberidou, Cynthia Ma, Sara A Hurvitz, Christine Rentzsch, Marion Rudolph, Silke Thiele, Oliver Boix, Gary Wilkinson, Eleni Lagkadinou, Matthias Ocker
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers 11 (12) (2019)
Alexander Hoemme, Holger Barth, Manuel Haschke, Stephan Krähenbühl, Florian Strasser, Claudia Lehner, Alexander von Kameke, Thomas Wälti, Beat Thürlimann, Martin Früh, Christoph Driessen, Markus Joerger
Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer. Cancer chemotherapy and pharmacology 83 (4) (2019)
Anne Schett, Sacha I Rothschild, Alessandra Curioni-Fontecedro, Stephan Krähenbühl, Martin Früh, S Schmid, Christoph Driessen, Markus Joerger
Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC. Cancer chemotherapy and pharmacology 85 (1) (2019)
Odharnaith O'Brien, Mark C Wright, Cathal O'Brien, Orla Geoghegan, Niamh Leonard, Siobhan Nicholson, Sinéad Cuffe, Aurelie Fabre, Wolfram Jochum, Markus Joerger, Steven G Gray, Stephen P Finn
Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples. Diagnostics (Basel, Switzerland) 9 (1) (2019)